Expert consensus on the diagnosis and treatment of EGFR gene mutation non-small cell lung cancer
Abstract
Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensification, perioperative and stage III targeted strategies, and mechanism-directed treatment after acquired resistance. Methods: A multidisciplinary expert panel reviewed high-level evidence from peer-reviewed publications and major oncology meetings from 2024 to 2026(ASCO, ESMO, WCLC et.al), with emphasis on clinical applicability in China. Recommendations were formulated according to molecular subtype, disease stage, metastatic pattern, resistance mechanism, drug accessibility, safety and multidisciplinary decision-making. Consensus statements were developed via a modified Delphi process in alignment with MMR submission requirements. Results: Third-generation EGFR-TKIs remain the preferred backbone for EGFR exon 19 deletion and L858R-mutant advanced NSCLC. First-line intensified strategies, including osimertinib plus platinum-pemetrexed chemotherapy, aumolertinib plus chemotherapy, and amivantamab plus lazertinib, may be considered for selected high-risk patients. Osimertinib consolidation after definitive chemoradiotherapy has established a standard strategy for unresectable stage III EGFR-mutated NSCLC. For EGFR exon 20 insertion mutations, amivantamab plus chemotherapy and emerging selective oral TKIs have changed the therapeutic paradigm. After EGFR-TKI resistance, repeat molecular profiling is recommended to guide MET-directed combinations, next-generation TKIs, antibody-drug conjugates, bispecific antibodies or chemotherapy-based regimens. Conclusions: This consensus provides a practical framework for diagnosis, molecular testing, treatment selection, resistance management and toxicity control in EGFR-mutated NSCLC in China. Keywords: EGFR-mutated NSCLC; Osimertinib; Targeted therapy; Resistance mechanisms; Consensus.